Your browser doesn't support javascript.
loading
Evaluating in vivo effectiveness of sotrovimab for the treatment of Omicron subvariant BA.2 versus BA.1: a multicentre, retrospective cohort study.
Lo, Carson K L; Lo, Calvin K F; Komorowski, Adam S; Leung, Victor; Matic, Nancy; McKenna, Susan; Perez-Patrigeon, Santiago; Sheth, Prameet M; Lowe, Christopher F; Chagla, Zain; Bai, Anthony D.
Afiliación
  • Lo CKL; Division of Infectious Diseases, Department of Medicine, McMaster University, Hamilton, ON, Canada. carson.lo@medportal.ca.
  • Lo CKF; Transplant Infectious Diseases and Ajmera Transplant Centre, University Health Network, 585 University Avenue, MaRS Building, 9th Floor, Toronto, ON, M5G 2N2, Canada. carson.lo@medportal.ca.
  • Komorowski AS; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Leung V; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
  • Matic N; Medical Microbiology, Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.
  • McKenna S; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Perez-Patrigeon S; Division of Medical Microbiology and Virology, St. Paul's Hospital, Providence Health Care, Vancouver, BC, Canada.
  • Sheth PM; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Lowe CF; Division of Medical Microbiology and Virology, St. Paul's Hospital, Providence Health Care, Vancouver, BC, Canada.
  • Chagla Z; Department of Pharmacy Services, Kingston Health Sciences Centre, Kingston, ON, Canada.
  • Bai AD; Division of Infectious Diseases, Department of Medicine, Queen's University, Kingston, ON, Canada.
BMC Res Notes ; 17(1): 37, 2024 Jan 24.
Article en En | MEDLINE | ID: mdl-38267971
ABSTRACT

BACKGROUND:

In vitro data suggested reduced neutralizing capacity of sotrovimab, a monoclonal antibody, against Omicron BA.2 subvariant. However, limited in vivo data exist regarding clinical effectiveness of sotrovimab for coronavirus disease 2019 (COVID-19) due to Omicron BA.2.

METHODS:

A multicentre, retrospective cohort study was conducted at three Canadian academic tertiary centres. Electronic medical records were reviewed for patients ≥ 18 years with mild COVID-19 (sequencing-confirmed Omicron BA.1 or BA.2) treated with sotrovimab between February 1 to April 1, 2022. Thirty-day co-primary outcomes included hospitalization due to moderate or severe COVID-19; all-cause intensive care unit (ICU) admission, and all-cause mortality. Risk differences (BA.2 minus BA.1 group) for co-primary outcomes were adjusted with propensity score matching (e.g., age, sex, vaccination, immunocompromised status).

RESULTS:

Eighty-five patients were included (15 BA.2, 70 BA.1) with similar baseline characteristics between groups. Adjusted risk differences were non-statistically significant between groups for 30-day hospitalization (- 14.3%; 95% confidence interval (CI) - 32.6 to 4.0%), ICU admission (- 7.1%; 95%CI - 20.6 to 6.3%), and mortality (- 7.1%; 95%CI - 20.6 to 6.3%).

CONCLUSIONS:

No differences were demonstrated in hospitalization, ICU admission, or mortality rates within 30 days between sotrovimab-treated patients with BA.1 versus BA.2 infection. More real-world data may be helpful to properly assess sotrovimab's effectiveness against infections due to specific emerging COVID-19 variants.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Neutralizantes / Anticuerpos Monoclonales Humanizados / COVID-19 Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: BMC Res Notes Año: 2024 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Neutralizantes / Anticuerpos Monoclonales Humanizados / COVID-19 Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: BMC Res Notes Año: 2024 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Reino Unido